Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][5] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Developments - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective approach to treating chronic pain and other conditions [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company's Proprietary Catheter-Based Technology